Cannabis
Legal Marijuana Market to Exhibit a Remarkable Hike of USD 127.49 Million by 2030, Size, Share, Rising Trends, Demand, Future Growth and Opportunity Analysis
<!– Name:DistributionId Value:8790419 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:5377 –> <!– Name:CustomerId Value:1201301 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:2d4345bb-25cd-4f93-be7c-680e351e6b7f –>
CHICAGO, March 17, 2023 (GLOBE NEWSWIRE) — Data Bridge Market research has published a report on the “Legal Marijuana Market” which covers several regions including the USA, Europe, China, Japan, India, South East Asia, and more. The report provides a comprehensive analysis of the market’s opportunities and risks and helps decision-makers make strategic and tactical decisions with confidence. A systematic analysis of patents and major market players has been carried out in the excellent Legal Marijuana report to provide a competitive landscape. This market report offers market segmentation in the most-detailed pattern. A high-level market analysis of major segments has been performed in the report and opportunities are identified. The market report not only deals with major industrial categories but also different associated segments such as services, technologies, & applications. What is more, the comprehensive Legal Marijuana market research report provides market data in such a way that it also considers new product development from beginning to launch.
After identifying trends in consumer and supply chain dynamics, marketing, promotional and sales strategies are interpreted accordingly for an utmost success. A high quality Legal Marijuana market report helps in finding out prospective in new geographical markets and performs market analysis to successfully get bigger into them. The report is also helpful to gain knowledge and insights about the new regulatory environment which suits to the organization. To design Legal Marijuana market survey report at its best, DBMR team works with respect to opportunities, challenges, drivers, market structures, and competitive landscape for maximum success of the clients.
Data Bridge Market Research analyses that the legal marijuana market, which was USD 27.7 billion in 2022, would rise to USD 127.49 million by 2030 and is expected to undergo a CAGR of 21% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Download Sample PDF of the Legal Marijuana Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-legal-marijuana-market
Marijuana signifies the dried leaves, stems, flowers, and seeds from the cannabis sativa or cannabis indica plant. It is also commonly known as cannabis. This plant is generally used as a recreational drug for numerous diseases. The legality of marijuana for recreational and medical is being done across many regions concerning its cultivation, possession, and distribution.
In the past few years, the use of marijuana as a recreational drug has been proven in many countries. Countries such as Uruguay, Canada, and numerous U.S. states have legalized the production, sale, and ownership of marijuana for medical and recreational usage. Several studies were carried out, which showed that medical marijuana and its derivatives could be used to treat symptoms of numerous diseases such as chemotherapy-induced nausea, chronic pain, Parkinson’s, Alzheimer’s, and other neurological diseases.
Recent Development
- In 2022, HYTN Innovations Inc. entered into a manufacturing and sales agreement with Promethean BioPharma. Through this agreement, the company has successfully created, and exported cannabis nano-emulsions that include its proprietary Elevation Technology in the medical cannabis market in Australia.
Competitive Landscape
The research promotes high-end commercialization and profit-steering opportunities, and it takes market dimensions and volatility into account.
This section of the report also focuses on accurately decoding the competitive landscape with astute high-end identification of frontline players, complete with an in-depth analytical study of their business choices and investment discretion, to ensure thoroughly impeccable investor participation and noteworthy growth prospects.
To ensure a smooth ride and hopeful business returns despite numerous odds and unprecedented hurdles, this research has carefully gauged facts pertaining to portfolio advancements, geographical presence, and other essential market details.
Some of the major players operating in the legal marijuana market are:
- VIVO Cannabis Inc. (Canada)
- Dr. Hemp Me. (Ireland)
- QC Infusion (U.S.),
- Hemp Production Services (Canada)
- Green Roads (U.S.)
- Royal CBD (U.S.)
- CV Sciences, Inc. (U.S.)
- Gaia Herbs Farm (U.S.)
- SPRING CREEK LABS (U.S.)
- Isodiol International Inc (Canada)
- Medical Marijuana, Inc. (U.S.)
Download the Complete Research Study Here in PDF Format @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-legal-marijuana-market
The investment made in the study would provide you access to information such as:
- Legal Marijuana Market [Global – Broken-down into regions]
- Regional level split [North America, Europe, Asia Pacific, South America, Middle East & Africa]
- Country wise Market Size Split [of important countries with major market share]
- Market Share and Revenue/Sales by leading players
- Market Trends – Emerging Technologies/products/start-ups, PESTEL Analysis, SWOT Analysis, Porter’s Five Forces, etc.
- Legal Marijuana Market Size
- Market Size by application/industry verticals
- Market Projections/Forecast
Opportunities for Key Players:
- Increasing Healthcare Expenditure Provided by Organizations
There is huge healthcare spending by various organizations that enhances the market growth. For instance, Verano Holdings, the Cannabis multistate operator, has received an additional USD 100 million under its credit agreement for multiple strategic initiatives and fund expansion. The main asset in the acquisition will be the vertical medical marijuana business based in New York, one of the only licensed operations in that state. Thus, this factor increases the market growth.
- Increasing Industrial Development
With the legalization of marijuana, a lot of countries are paving the way for its cultivation to cut imports and gain revenue in the form of taxes. This, in turn, led to an increasing number of jobs in the industry and many more companies are focusing in this territory. Numerous startups in the U.S. and Europe are now primarily focusing on alternate uses of cannabis other than recreational and medicinal. Thus, all these factors led to significant industrial expansion worldwide. This factor boosts market growth.
Key Market Segments Covered in Legal Marijuana Industry Research
Species
Strains
Type
- Recreational Marijuana
Application
- Chronic Pain
- Mental Disorders
Product Type
- Buds / marijuana Flower
- Cannabis Extracts
Purchase Channel
End-User
- Pharmaceutical
- Personal Care
- Research and Development Centers
Browse More About This Research Report @ https://www.databridgemarketresearch.com/reports/global-legal-marijuana-market
Market Drivers:
- Higher Demand for Marijuana Oils
The increasing demand for marijuana oil is enhancing market growth. The majority of countries have legalized marijuana for its medicinal properties. Marijuana oil and tinctures are being studied on a huge scale for multiple indications in many countries. This is also anticipated to evolve as the fastest-growing segment due to recent legalizations for medical cannabis and its derivatives. Oils extracted from cannabis are used for the treatment of vomiting and nausea occurring due to cancer. Thus, these devices are boosting the market’s growth.
- Utilization of Marijuana in Chronic Disorders
Cannabis derivatives have been widely studied for their analgesic use in chronic disorders. It has shown far better results with few side effects compared to the regular medicines being prescribed till now. It has proven to decrease arthritic pain considerably with negligible side effects. With the rise in awareness of medical cannabis and its derivatives, the market is anticipated to grow progressively over the forecast period. Thus, this factor will boost market growth.
Legal Marijuana Market Regional Analysis/Insights:
The countries covered in the legal marijuana market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the legal marijuana market due to government regulations and the legalization of marijuana for medical and adult (recreational) use within the region. It is further boosted by the presence of most of the major market players in the cannabis market. The demand and supply have increased, with more than two-thirds of the U.S. falling under the legal territory for cannabis
Asia-Pacific is expected to grow significantly due to the increasing demand in these regions. Numerous countries are legalizing cannabis in the Asia Pacific region. Countries with a large elderly population will fast approve the legalization process due to its medicinal value, which can increase the industry’s growth in the region.
Table of Contents:
- Introduction
- Market Segmentation
- Executive Summary
- Premium Insights
- Global Legal Marijuana Market: Regulations
- Market Overview
- Global Legal Marijuana Market, By Species
- Global Legal Marijuana Market, By Strains
- Global Legal Marijuana Market, By Type
- Global Legal Marijuana Market, By Application
- Global Legal Marijuana Market, By Product Type
- Global Legal Marijuana Market, By Purchase Channel
- Global Legal Marijuana Market, By End-User
- Global Legal Marijuana Market, By Region
- Global Legal Marijuana Market: Company Landscape
- SWOT Analyses
- Company Profile
- Questionnaires
- Related Reports
Download the Full Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-legal-marijuana-market
Explore More Reports:
- Medical Marijuana Market, By Form (Solid, Gas, Dissolvable/Powders), Product Type (Buds, Oils, Tinctures, Others), Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD)), Type (Flowers, Concentrates, Edibles, Others), Application (Chronic Pain, Arthritis, Cancer, Neurology, Oncology, Others), Route of Administration (Inhalation, Oral, Topical), Distribution Channel (Retail and Pharmacy Stores, Online Platforms), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-medical-marijuana-market
- Medical Cannabis Market, By Product (Oil, Dried Medical Cannabis, Medical Cannabis Capsules, Vape Pen, Whole Flower, Creams and Moisturizer, Ground Flower, Patch, Mask and Serum, Cleanser, Others), Source (Natural, Synthetic), Species (Sativa, Hybrid, Cannabis Indica), Derivatives (Cannabidiol (CBD), Tetrahydrocannabinol (THC)/Delta-8-Tetrahydrocannabinol, Cannabigerol (CBG), Cannabinol, Others), Application (Pain Management, Anxiety, Muscle Spasms, Nausea, Appetite Loss, Cancer, Arthritis, Alzheimer’s Disease, Epilepsy, Depression and Sleep Disorders, Multiple Sclerosis, Autism, Mental Health Conditions, Elevate Mood, Others), Route of Administration (Oral Solutions and Capsules, Smoking, Topicals, Vaporizers, Others), End User (Homecare Settings, Hospital and Rehab Centers, Pharmaceutical Industry, Research and Development Centers, Others), Distribution Channel (B2C, B2B) https://www.databridgemarketresearch.com/reports/global-medical-cannabis-market
- Cannabis Infused Products Market, By Product (Skincare, Cosmetics, Haircare, Intimate Lubricants, Pharmaceuticals, Gummies, Pills, Infused Beverages, and Others), Source (Hemp, Marijuana), Distribution Channel (B2B, B2C), End User (Medical, Personal Use, Pharmaceuticals, Wellness) https://www.databridgemarketresearch.com/reports/global-cannabis-infused-products-market
- Cannabis Capsule Market, By Product (High THC Capsule, THC/CBD Balanced Capsules, High CBD Capsules Digital), Compound (Tetrahydrocannabinol (THC)-Dominant, Cannabidiol (CBD)-Dominant), Application (Medical, Recreational), End User (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Sales) https://www.databridgemarketresearch.com/reports/global-cannabis-capsule-market
- U.S. Cannabis Seeds Market, By Seed Type (Regular Seeds, Feminized Seeds, Autoflowering Seeds), Strain (Indica, Hybrid, Sativa), Compound (THC Dominant, CBD Dominant, Balanced THC and CBD), Category (Inorganic, organic), Distribution Channel (Store Based Retailing, Online/E-Commerce Retailing), Type of Vendors (Resellers, Breeders, Seeds Manufacturing Companies) https://www.databridgemarketresearch.com/reports/us-cannabis-seeds-market
- Cannabis Gummies Market By Concentration (High, Low Concentration), Distribution Channel (Online and Offline), Type (Solid Edible, Topical Edible, Inhalation and Liquid Edible), Preparation (Cannabidiol and Tetrahydrocannabinol), Application (Cancer, Epilepsy, Arthritis, Multiple Sclerosis, Alzheimer, Anorexia and Nausea) https://www.databridgemarketresearch.com/reports/global-cannabis-gummies-market
- Cannabis Medicine Market, By Product Type (Prescription Drugs, Recreational Drugs, Others), Application (Chronic Pain, Mental Disorders, Cancer, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-cannabis-medicine-market
- Cannabis Testing Market, By Product and Software (Cannabis Testing Products, Cannabis Testing Software), Type (Potency Testing, Terpene Profiling, Residual Solvent Screening, Microbial Analysis, Pesticide Screening, Heavy Metal Testing, Genetic Testing), End User (Product and Software, Services), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-cannabis-testing-market
- Cannabis Pharmaceutical Market, By Product Type (Capsules, Concentrates, Edibles, and Other), Drugs (Epidiolex, Marinol, Cesamet, Sativex, Others), Compound Type (Tetrahydrocannabinol (THC), Cannabidiol (CBD), and Balanced THC & CBD), Application (Inflammation, Chronic Pain, Epilepsy, Sleep Disorders, Anorexia, Schizophrenia, Others), End-Users (Clinic, Hospital, others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-cannabis-pharmaceutical-market
- Thailand Medical Cannabis Market, By Product (Oil, Dried Medical Cannabis, Medical Cannabis Capsules, Vape Pen, Whole Flower, Creams & Moisturiser, Ground Flower, Patch, Mask & Serum, Cleanser, and Others), Application (Pain Management, Anxiety, Muscle Spasms, Nausea, Appetite Loss, Cancer, Arthritis, Alzheimer’s Disease/Migraines, Epilepsy, Depression and Sleep Disorders, Multiple Sclerosis, Autism, Mental Health Conditions, Elevate Mood, and Others), Derivatives (Cannabidiol (CBD), Tetrahydrocannibinol (THC)/Delta-8-Tetrahydrocannabiol, Patch, Cannabigerol (CBG), Cannabinol (CBN), and Others), Source (Natural, Synthetic), Species (Sativa, Hybrid, Cannabis Indica), Route of Administration (Oral Solutions and Capsules, Smoking, Topicals, Vaporizers, and Others), End User (Homecare Setting, Hospital, Rehab Centres, Pharmaceutical Industry, Research and Development Centres, and Others), Distribution Channel (B2C, B2B), Country (Thailand) https://www.databridgemarketresearch.com/reports/thailand-medical-cannabis-market
- X-Ray Detectors Market, By Type (Flat Panel Detector, Computed Radiography Detectors, Line Scan Detectors, Charged Coupled Device (CCD) Detectors and Mobile Detectors), Panel Size (Small Area and Large Area), Portability (Fixed Detectors and Portable Detectors), Application (Medical Imaging, Dental Application, Security Application, Veterinary Application and Industrial Application), End User (Hospitals, Diagnostic Laboratories, Original Equipment Manufacturers (OEM’S), Clinics and ICU) https://www.databridgemarketresearch.com/reports/global-x-ray-detectors-market
- Insulin Glargine Market, By Type (Single Dose Vial and Pre-Filled Syringe), Application (Treat Type 2 Diabetes and Treat Type 1 Diabetes), Distribution Channel (Hospital Pharmacy, Online Sales, Retail Pharmacy and Other Distribution Channels), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-insulin-glargine-market
- Antibiotics Market, By Indication (Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections and Others), Drug Class (Beta Lactam and Beta Lactamase Inhibitors, Quinolone, Macrolide, Others), Drug Origin (Natural, Semisynthetic, Synthetic), Spectrum of Activity (Broad-spectrum Antibiotic, Narrow-spectrum Antibiotic), Route of Administration (Oral, Parenteral, Topical, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy Others) https://www.databridgemarketresearch.com/reports/global-antibiotics-market
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- [email protected]
Cannabis
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
Cannabis
IM Cannabis Reports First Quarter Financial Results
IMC prepares for accelerated growth after legalization in Germany and recovers from the impact of the Israel-Hamas war.
TORONTO and GLIL YAM, Israel, May 8, 2024 /PRNewswire/ — IM Cannabis Corp. (the “Company” or “IMC“) (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2023, unless otherwise stated.
Q1 2024 Financial Highlights
- 13% Revenue increase vs. Q4 2023 of $12.1M vs. $10.7M and 4% decrease vs. Q1 2023 of $12.5M
- 125% Gross profit increase vs. Q4 2023 of $1.8M vs. $0.8 and 39% Gross profit decrease vs. Q1 2023 of $2.9M
- 29% decrease in operating expenses vs. Q1 2023 excluding the one-time Oranim revoke related losses of $4.6M vs. $6.5M and 14% increase including Oranim
- 12% increase of Non-IFRS Adjusted EBITDA loss to $2.1M
Operational Highlights
The Company intends to complete a non-brokered private placement (the “Offering“) of secured convertible debentures of the Company (each, a “Debenture“) for aggregate proceeds of up to C$2,500,000. The Debentures will mature on the date that is 12 months from the date of issuance and will not incur interest except in the event of default. The Debentures are being issued to holders of short term loans and obligations owed by the Company or its wholly owned subsidiaries. The principal of the Debenture may be converted into common shares in the Company (each, a “Share“) at a conversion price of $1.08 per Share.
Management Commentary
“With the April 1st cannabis legalization in Germany, we are augmenting our focus and resources on the German market, where we expect to see the biggest growth potential, and the best return on investment. While it is still too early to make any predictions, our sales in Germany almost doubled during the month of April,” said Oren Shuster, Chief Executive Officer of IMC. “Looking back on the first month post legalization in Germany, I see that we have the infrastructure and the supply agreements in place to continue delivering the accelerated growth we have already seen in April. We will also ensure that we have the necessary resources in place for success.”
“In 2023 we completely restructured, becoming a very lean and agile company, leaning into active cost management. This process is reflected in the numbers, our G&A decreased 27% vs Q1 2023” said Uri Birenberg, Chief Financial Officer of IMC. “While our results have recovered from the impact of the Israel-Hamas war, our revenue was still effected by both an unfavorable exchange rate, as well as price reductions to sell off inventory.”
Q1 2024 Conference Call
The Company will host a Zoom web conference call today at 9:00 a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration.
If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com/ within 24 hours after the call.
Q1 2024 Financial Results
- Revenues for the first quarter of 2024 were $12.1 million compared to $12.5 million in the first quarter of 2023, a decrease of 3%. The decrease is mainly due an exchange rate effect of about $0.2 million and decrease in avg. price per sale due to increased competition.
- Gross profit for the first quarter of 2024 was $1.8 million, compared to $2.9 million in Q1 2024, a decrease of 39%. The downside is attributed mainly to the slow-moving stock that was moved out at a lower price and an exchange rate difference totaling $0.4 million and $0.64 million cost of sales loss due to an inventory erase of the slow-moving stock. Company fair value adjustment was $0 and $0.4 million for the Q1 2024 and Q1 2023 respectively.
- Total Dried Flower sold in Q1 2024 was approximately 1,873 kg with an average selling price of $5.68 per gram, compared to approximately 1,842kg in Q1 2023, with an average selling price of $6.59 per gram. This difference is mainly due to increased competition within the retail segment, and mid-range stock discounts to move out slow moving stock.
- Total operating expenses in Q1 2024 were $7.4 million compared to $6.5 million in Q1 2023. The increase is due to the other operating expenses related to Oranim Deal revoke, with an expected losses of $2.8 million. Adjusting for this one-time losses, Q1 2024 operating expenses were $4.6 million compared to $6.5 million in Q1 2023, a decrease of 29%.
- G&A Expenses in Q1 2024 were $2.3 million, compared to $3.2 million in Q1 2023, a decrease of 28%. The decrease in the G&A expense is attributable mainly to salaries and professional services of $0.64 million.
- Selling and Marketing Expenses in Q1 2024 were $2.3 million, compared to $2.8 million in Q1 2023, a decrease of 18% mainly due to a decrease in Salaries and professional services of $0.5 million.
- Net Loss from continuing operations in Q1 2024 was $6.0 million, compared to $0.9 million in Q12023.
- Basic and diluted Loss per Share in Q1 2024 was $0.42, compared to a loss of $0.05 per Share in Q1 2023.
- Non-IFRS Adjusted EBITDA loss in Q1 2024 was $2.1 million, compared to an Adjusted EBITDA loss of $1.9 million in Q1 2023 an increase of 10%.
- Cash and Cash Equivalents as of March 31, 2024, were $1.0 million compared to $1.8 million in December 31, 2023.
- Total assets as of March 31, 2024, were $41.1 million, compared to $48.8 million in December 31, 2023, a decrease of 16%. The decrease is mainly attributed to the goodwill reduction due to Oranim agreement cancelation of about $2.8M, a reduction in Inventory of $2.1 million, reduction of Cash and cash equivalents of $0.8M and reduction in Trade payables of $1.2 million.
- Total Liabilities as of March 31, 2024, were $32.8 million, compared to $35.1 in December 31, 2023, a decrease of about 7%. The decrease was mainly due to the reduction in other accounts payables and accrued expenses of $1.8 million and reduction in the PUT option liability of $0.7 million.
The Company’s financial statements as of March 31, 2024 includes a note regarding the Company’s ability to continue as a going concern. The Company’s Q1 2024 financial results do not include any adjustments relating to the recoverability and classification of assets or liabilities that might be necessary should the Company be unable to continue as a going concern. For more information, please refer to the “Liquidity and Capital Resources” and “Risk Factors” sections in the Company’s management’s discussion and analysis for the quarter ended March 31, 2024.
Non-IFRS Measures
This press release makes reference to “Gross Margin” and “Adjusted EBITDA”, which are financial measures that are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. These measures are provided as complementary information to the Company’s IFRS measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should neither be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS.
For an explanation of how management defines Gross Margin and Adjusted EBITDA, see the Company’s management’s discussion and analysis for the period ended March 31, 2024, available under the Company’s SEDAR+ profile at www.sedarplus.ca on EDGAR at www.sec.gov/edgar.
We reconcile these non-IFRS financial measures to the most comparable IFRS measures as set out below.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION |
||||||
Canadian Dollars in thousands |
||||||
March 31, |
December 31, |
|||||
Note |
(Unaudited) |
|||||
ASSETS |
||||||
CURRENT ASSETS: |
||||||
Cash and cash equivalents |
$ 1,048 |
$ 1,813 |
||||
Trade receivables |
6,506 |
7,651 |
||||
Advances to suppliers |
780 |
936 |
||||
Other accounts receivable |
3,732 |
3,889 |
||||
Inventories |
3 |
7,901 |
9,976 |
|||
19,967 |
24,265 |
|||||
NON-CURRENT ASSETS: |
||||||
Property, plant and equipment, net |
4,939 |
5,058 |
||||
Investments in affiliates |
2,078 |
2,285 |
||||
Right-of-use assets, net |
1,243 |
1,307 |
||||
Intangible assets, net |
5,440 |
5,803 |
||||
Goodwill |
7,442 |
10,095 |
||||
21,142 |
24,548 |
|||||
Total assets |
$ 41,109 |
$ 48,813 |
||||
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION |
||||||
Canadian Dollars in thousands |
||||||
March 31, |
December 31, |
|||||
Note |
(Unaudited) |
|||||
LIABILITIES AND EQUITY |
||||||
CURRENT LIABILITIES:
|
||||||
Trade payables |
$ 9,511 |
$ 9,223 |
||||
Bank loans and credit facilities |
11,941 |
12,119 |
||||
Other accounts payable and accrued expenses |
4,440 |
6,218 |
||||
Accrued purchase consideration liabilities |
2,165 |
2,097 |
||||
PUT Option liability |
1,967 |
2,697 |
||||
Current maturities of operating lease liabilities |
461 |
454 |
||||
30,485 |
32,808 |
|||||
NON-CURRENT LIABILITIES:
|
||||||
Warrants measured at fair value |
4 |
137 |
38 |
|||
Operating lease liabilities |
744 |
815 |
||||
Long-term loans |
401 |
394 |
||||
Employee benefit liabilities, net |
96 |
95 |
||||
Deferred tax liability, net |
902 |
963 |
||||
2,280 |
2,305 |
|||||
Total liabilities |
32,765 |
35,113 |
||||
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY: |
5 |
|||||
Share capital and premium |
253,887 |
253,882 |
||||
Translation reserve |
1,399 |
95 |
||||
Reserve from share-based payment transactions |
9,664 |
9,637 |
||||
Accumulated deficit |
(255,431) |
(249,145) |
||||
Total equity attributable to equity holders of the Company |
9,519 |
14,469 |
||||
Non-controlling interests |
(1,175) |
(769) |
||||
Total equity |
8,344 |
13,700 |
||||
Total liabilities and equity |
$ 41,109 |
$ 48,813 |
||||
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS |
||||||
AND OTHER COMPREHENSIVE INCOME (UNAUDITED) |
||||||
Canadian Dollars in thousands, except per share data |
||||||
Three months ended March 31, |
||||||
Note |
2024 |
2023 (*) |
||||
Revenues |
$ 12,063 |
$ 12,529 |
||||
Cost of revenues |
10,274 |
9,286 |
||||
Gross profit before fair value adjustments |
1,789 |
3,243 |
||||
Fair value adjustments: |
||||||
Realized fair value adjustments on inventory sold in the period |
(10) |
(339) |
||||
Total fair value adjustments |
(10) |
(339) |
||||
Gross profit |
1,779 |
2,904 |
||||
General and administrative expenses |
2,332 |
3,175 |
||||
Selling and marketing expenses |
2,292 |
2,805 |
||||
Restructuring expenses |
– |
283 |
||||
Share-based compensation |
32 |
258 |
||||
Other operating expenses |
9 |
2,753 |
– |
|||
Total operating expenses |
7,409 |
6,521 |
||||
Operating loss |
5,630 |
3,617 |
||||
Finance income |
4 |
(14) |
3,530 |
|||
Finance expense |
(487) |
(795) |
||||
Finance income, net |
(501) |
2,735 |
||||
Gain (loss) before income taxes |
(6,131) |
(882) |
||||
Income tax benefit |
(111) |
(16) |
||||
Net )loss( gain |
(6,020) |
(866) |
||||
Other comprehensive income that will not be reclassified to profit or loss in |
||||||
Total other comprehensive income that will not be reclassified to profit or loss |
67 |
36 |
||||
Exchange differences on translation to presentation currency |
1,330 |
(562) |
||||
Total other comprehensive income (loss) that will not be reclassified to profit |
1,397 |
(526) |
||||
Other comprehensive income that will be reclassified to profit or loss in |
||||||
Adjustments arising from translating financial statements of foreign operation |
(35) |
155 |
||||
Total other comprehensive income (loss) that will be reclassified to profit or loss |
(35) |
155 |
||||
Total other comprehensive income (loss) |
1,362 |
(371) |
||||
Total comprehensive loss |
$ (4,658) |
$ (1,237) |
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS |
||||||
AND OTHER COMPREHENSIVE INCOME (UNAUDITED) |
||||||
Canadian Dollars in thousands, except per share data |
||||||
Three months ended March 31, |
||||||
Note |
2024 |
2023 (*) |
||||
Net income (loss) attributable to: |
||||||
Equity holders of the Company |
(5,623) |
(600) |
||||
Non-controlling interests |
(397) |
(266) |
||||
$ (6,020) |
$ (866) |
|||||
Total comprehensive income (loss) attributable to: |
||||||
Equity holders of the Company |
(4,252) |
(959) |
||||
Non-controlling interests |
(406) |
(278) |
||||
$ (4,658) |
$ (1,237) |
|||||
Net income (loss) per share attributable to equity holders of the Company: |
7 |
|||||
Basic and diluted (loss) gain per share (in CAD) |
$ (0.42) |
$ (0.05) |
||||
Earnings (loss) per share attributable to equity holders of the Company |
||||||
Basic and diluted (loss) gain per share (in CAD) |
$ (0.42) |
$ (0.05) |
||||
(*) See note 1 regarding figures disclosure. |
||||||
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
||||||
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |
||||
Canadian Dollars in thousands |
||||
Three months ended March 31, |
||||
2024 |
2023 (*) |
|||
Cash provided by operating activities: |
||||
Net income (loss) for the period |
$ (6,020) |
$ 43 |
||
Adjustments for non-cash items: |
||||
Fair value adjustment on sale of inventory |
10 |
339 |
||
Fair value adjustment on Warrants, investments and accounts receivable |
100 |
(3,636) |
||
Depreciation of property, plant and equipment |
147 |
174 |
||
Amortization of intangible assets |
452 |
456 |
||
Depreciation of right-of-use assets |
118 |
179 |
||
Impairment of goodwill |
2,753 |
– |
||
Finance expenses, net |
401 |
635 |
||
Deferred tax liability, net |
(69) |
(150) |
||
Share-based payment |
32 |
258 |
||
Restructuring expense |
– |
283 |
||
3,944 |
(1,462) |
|||
Changes in working capital: |
||||
Decrease (increase) in trade receivables |
1,332 |
1,937 |
||
Decrease (increase) in other accounts receivable and advances to suppliers |
159 |
(940) |
||
Decrease (increase) in inventories, net of fair value adjustments |
2,159 |
90 |
||
Decrease (increase) in trade payables |
663 |
(6,021) |
||
Changes in employee benefit liabilities, net |
– |
(22) |
||
Increase in other accounts payable and accrued expenses |
(2,745) |
(14) |
||
1,568 |
(4,970) |
|||
Taxes (paid) received |
(121) |
328 |
||
Net cash used in operating activities |
(629) |
(6,061) |
||
Cash flows from investing activities: |
||||
Purchase of property, plant and equipment |
(2) |
(411) |
||
Payment of purchase consideration |
– |
(56) |
||
Net cash used in investing activities |
$ (2) |
$ (467) |
||
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |
||||
Canadian Dollars in thousands |
||||
Three months ended March 31, |
||||
2024 |
2023 |
|||
Cash flow from financing activities: |
||||
Proceeds from issuance of share capital, net of issuance costs |
176 |
825 |
||
Proceeds from issuance of warrants |
(176) |
7,027 |
||
Repayment of lease liability |
(118) |
(175) |
||
Interest paid – lease liability |
(15) |
(18) |
||
Receipt (repayment) of bank loan and credit facilities |
(2,856) |
(1,046) |
||
Cash paid for interest |
(444) |
(56) |
||
Proceeds from discounted checks |
2,581 |
|||
Net cash (used in) provided by financing activities |
(852) |
6,557 |
||
Effect of foreign exchange on cash and cash equivalents |
718 |
(1,059) |
||
Decrease in cash and cash equivalents |
(765) |
(1,030) |
||
Cash and cash equivalents at beginning of the period |
1,813 |
2,449 |
||
Cash and cash equivalents at end of the period |
$ 1,048 |
$ 1,419 |
||
Supplemental disclosure of non-cash activities: |
||||
Right-of-use asset recognized with corresponding lease liability |
$ 40 |
$ 49 |
||
Issuance of shares in payment of debt settlement to a non-independent director of the company |
$ – |
$ 222 |
||
(*) See note 1 regarding Figures disclosure. |
||||
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company also operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries. The Company has exited operations in Canada and considers these operations as discontinued.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the impact of the Israel-Hamas war on the Company, including its operations and the medical cannabis industry in Israel; the timing and impact of the legalization of medicinal cannabis in Germany, including, the Company having it “all in house”; the Company being positioned to take advantage of the legalization; the Company’s growth in 2024; the market growth for medicinal cannabis in Germany; the stated benefits of the Company’s EU-GMP processing facility and an EU-GDP logistics center; the Company to host a teleconference meeting as stated; and the Company’s stated goals, scope, and nature of operations in Germany, Israel, and other jurisdictions the Company may operate.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to focus and resources to achieve sustainable and profitable growth in its highest value markets; the Company’s ability to mitigate the impact of the Israel-Hamas war on the Company; the Company’s ability to take advantage of the legalization of medicinal cannabis in Germany; the Company’s ability to host a teleconference meeting as stated; and the Company’s ability to carry out its stated goals, scope, and nature of operations in Germany, Israel, and other jurisdictions the Company may operate.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to host a teleconference meeting as stated.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
+972-77-3603504
Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-reports-first-quarter-financial-results-302139688.html
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis1 week ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt1 week ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
SCHWAZZE1 week ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis1 week ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis1 week ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis1 day ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis7 hours ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0